MedPage Today recently released the following reports on the effectiveness of anti-VEGF (vascular endothelial growth factor) treatment for people with diabetic macular edema (DME) and nonproliferative diabetic retinopathy (NPDR).
Although there are many anti-VEGF described in the literature like Bevacizumab, Ranibizumab, Pegaptanib, Anecortave acetate, VEGF-trap, Squalamine lactate, Combretastatin A4 Prodrug, AdPEDF, SiRNA, Cand5, TG100801, the ones that have been most studied are Bevacizumab (Avastin; Genentech, Inc., CA) Ranibizumab (Lucentis; Genentech, Inc., CA), and Pegaptanib sodium (Macugen; Eyetech, Inc., NY).
Here are a two reports from MedPage Today in July 2018 that may be of interest to you:
New Drugs Show Promise in Retinopathy: Bi-specific antibody, integrin inhibitor move to phase III